EU Commission approves Barry Callebaut's health claim: Cocoa flavanols support a healthy blood circulation

• Official validation: Cocoa flavanols contribute to normal blood circulation in human body by helping to maintain elasticity of blood vessels 

• New market potential for Barry Callebaut's ACTICOA^® cocoa powder and dark chocolate products  

• Barry Callebaut's ACTICOA^® process is the result of year-long research into preserving cocoa flavanols 

Barry Callebaut now has the proprietary right to use the cocoa flavanols claim within EU countries. The claim can be used for cocoa beverages (with cocoa powder) or for dark chocolate providing at least a daily intake of 200 mg of cocoa flavanols. Barry Callebaut will be able to use the claim for its ACTICOA^® cocoa and chocolate products which retain most of the cocoa flavanols naturally present in the cocoa bean.

Barry Callebaut's customers who use ACTICOA^® cocoa and chocolate products can apply the claim on their products and packaging. With this, they will be able to differentiate their offerings from other products on the market. Barry Callebaut sees new market potential to use the cocoa flavanols claim for - among others - applications in chocolate drinks, products using dark chocolate and even for the pharmaceutical industry.

Peter Boone, Chief Innovation Officer at Barry Callebaut, said: "Receiving the right to use a health claim on cocoa flavanols by the EU Commission is most valuable for us as it is a great reward for long years of extensive research. The health claim is opening up new market potential. Since we received the positive opinion from EFSA on our submitted health claim, we saw a lot of interest among our customers."

Herwig Bernaert, Head of Discovery Programs and Global Projects at Barry Callebaut, added: "The EU Commission's approval marks a milestone in our research efforts in the healthy ingredients of the cocoa bean. We are very happy to be able to offer our ACTICOA^® products with a health claim now, a real competitive differentiator for our customers."

In July 2012, Barry Callebaut was the first company in the EU to obtain a positive Scientific Opinion on a health claim on cocoa flavanols by EFSA. Since 2005, the company has carried out more than 20 human clinical studies examining various impacts of cocoa flavanols on the human body functions. For these studies, Barry Callebaut used products made through its own developed ACTICOA^® process. The company's specific ACTICOA^® process is the outcome of years of research into ways of preserving cocoa flavanols. Barry Callebaut succeeded in maintaining up to 80% of the cocoa flavanols which would otherwise be destroyed for the most part during the conventional chocolate-making process.

***

Barry Callebaut (www.barry-callebaut.com):
With annual sales of about CHF 4.8 billion (EUR 4.0 billion / USD 5.2 billion) in fiscal year 2011/12, Zurich-based Barry Callebaut is the world's leading manufacturer of high-quality cocoa and chocolate products - from sourcing and transforming cocoa beans to producing the finest chocolate, including chocolate fillings, decorations and compounds. Combined with the recently acquired cocoa ingredients business from Petra Foods, Barry Callebaut generates estimated annual sales of CHF 6 billion (EUR 4.9 billion / USD 6.4 billion), runs around 50 production facilities worldwide, sells its products in over 100 countries and employs a diverse and dedicated workforce of more than 8,000 people.
Barry Callebaut serves the entire food industry, from industrial food manufacturers to artisanal and professional users of chocolate, such as chocolatiers, pastry chefs, bakers, hotels, restaurants or caterers. The two global brands catering to the specific needs of these customers are Callebaut^® and Cacao Barry^®

***

Contacts

[1] See also previous announcement of July 17, 2012: "EFSA issues positive Scientific Opinion on Barry Callebaut's health claim on cocoa flavanols".

PDF version and image see below links: